Ronopterin - vasopharm BIOTECH

Drug Profile

Ronopterin - vasopharm BIOTECH

Alternative Names: VAS-203

Latest Information Update: 20 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator vasopharm BIOTECH
  • Class Neuroprotectants; Pteridines; Small molecules
  • Mechanism of Action Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain injuries
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Brain injuries

Most Recent Events

  • 15 Mar 2018 Adverse events data from a phase I trial in Brain injuries released by vasopharm BIOTECH (NCT02992236)
  • 01 Nov 2016 vasopharma BIOTECH completes a phase I pharmacodynamics trial in Healthy volunteers Germany (IV) (NCT02992236)
  • 07 Oct 2016 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top